---
layout: default
title: Home
---
<div class="flexslider">
    <ul class="slides">
        <li>
            <img src="/images/hero4.jpg" class="editable" />
        </li>
        <li>
            <img src="/images/hero6.jpg" class="editable" />
        </li>
        <li>
            <img src="/images/hero2.jpg" class="editable" />
        </li>
        <li>
            <img src="/images/hero5.jpg" class="editable" />
        </li>
        <li>
            <img src="/images/hero3.jpg" class="editable" />
        </li>

    </ul>
</div>
    <div class="container">
        <div class="row">
            <div class="col-sm-12">
                <div class="tagline">
                    <h3 class="editable"><strong>Quintessence Biosciences</strong> is working to improve the lives of patients<br />by developing new drugs based on EVade&trade;&nbsp;Ribonuclease technologies.</h3>
                </div>
            </div>
        </div>
    </div>
    <div class="spotlight">
        <div class="container">
            <div class="row">
                <div class="col-sm-2">
                    <img src="/images/spotlight.png" class="editable" />
                </div>
                <div class="col-sm-10">
                    <h2 id="upcoming" class="editable">Spotlight: Lead&nbsp;EVade&trade; RNase QBI-139</h2>
                    <p class="editable">Our approach provides the only protein-based means to target the RNA in cancer cells. Our EVade&trade;&nbsp;ribonucleases have selectivity for cancer cells due to their affinity for the anionic glycans that are overexpressed in cancer. Our lead candidate, called QBI-139, has a strong therapeutic window against a variety of <em>in vivo</em> solid tumors in xenograft models including: colon, non-small cell lung, ovarian, pancreatic and prostate cancer. A first in human, dose escalation Phase I trial &nbsp;in patients with solid tumors showed that&nbsp;QBI-139 has a favorable safety profile, without the common side effects of chemotherapies (e.g. myelosuppression). At the higher dose levels, QBI-139 showed an increased rate of stable disease as well as changes in serum markers for two prostate cancer patients.<br /></p>
                </div>
            </div>
        </div>
    </div>
    <div id="upcoming-events">
        <div class="container">
            <div class="row">
                <div id="eventsTitle">
                    <h2 class="editable">Upcoming Events</h2>
                    <p class="editable">See where Quintessence Biosciences is presenting in the coming months.</p>
                    <a href="/events/">View All Upcoming Events</a>
                </div>
                {% assign sorted_events = (site.data.events | sort: 'date' %}
                {% for event in sorted_events limit:3 %}
                    <div class="col-sm-12 col-md-4">
                        <div class="new-event clearfix">
                            <div class="event-border">
                                <img src="/images/event_border.png" />
                            </div>
                            <div class="event-info">
                                <p class="editable"><strong>
                                        {{event.title}}<br />{{event.date | date: '%B %d, %Y' }}<br />
                                        <a href="{{event.link}}" target="_blank">Agenda</a>
                                    </strong></p>
                                <p class="editable">Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the ASCO Annual Meeting in Chicago. 1</p>
                            </div>
                        </div>
                    </div>
                {% endfor %}
                </div>
        </div>
    </div>


